Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis

摘要: The aim of this study was to understand the clinical features and treatment outcome Chinese patients with multiple myeloma (MM). This retrospective enrolled 940 newly diagnosed inpatients (median age, 59 years; immunoglobulin (Ig)D isotype, 6.5%) complete follow-up data at three centers. In all, 85.8% were Durie-Salmon stage III 48.3% International Staging System (ISS) diagnosis. Also, 9.6% had extramedullary plasmacytoma. Compared IgG, IgD-type a younger more ISS III, hypercalcemia, elevated levels lactate dehydrogenase, hyperuricemia, renal dysfunction 1q21 amplification (P=0.03). overall survival (OS) benefit prominent in IgG than IgD when received bortezomib; however, they showed no significant difference older therapies such as melphalan combined prednisone or vincristine adriamycin dexamethasone. Fluorescence situ hybridization (FISH) results that 17.6% 17p13 deletion. Conventional cytogenetics revealed 13.3% hypodiploid those cases worst survival, but hyperdiploid (9.3%) did not show any compared normal karyotype (77.4%). Median OS progression-free for all 54 26 months, respectively. Significant factors by multivariate analysis gender, stage, number FISH abnormalities disease. MM mainland China presents different features, being age having higher risk receiving bortezomib.